Develops glaucoma treatments, including micro-scale surgical devices and sustained-release pharmaceuticals.
Jun 2026Revenue $613M/yrExpenses $806M/yr
Fell below break-even Aug 2017Cash runway ≈ 9.4 years from Jun 2026
Figures by year
When will GLAUKOS be profitable again?
Its expenses passed its revenue in Aug 2017. In the 12 months to Jun 2026, revenue was $613M and expenses $806M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $507M | $707M | −$200M |
| Dec 2024 | $383M | $506M | −$122M |
| Dec 2023 | $315M | $443M | −$129M |
| Dec 2022 | $283M | $365M | −$82.3M |
| Dec 2021 | $294M | $327M | −$32.9M |
| Dec 2020 | $225M | $349M | −$124M |
| Dec 2019 | $237M | $287M | −$50.3M |
| Dec 2018 | $181M | $194M | −$13.0M |
| Dec 2017 | $159M | $162M | −$2.28M |
| Dec 2016 | $114M | $110M | $4.24M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.